Generian

Generian is building a first-in-class drug discovery pipeline of small molecule drugs to address the shortcomings of biologics and improve the patient experience by increasing convenience and access. By leveraging a unique and versatile drug discovery approach that can screen proteins of interest in their native cellular environment, we have the potential to discover small molecules against previously challenging to drug protein targets. By rapidly identifying target binders, Generian progresses candidates with greater mechanistic certainty and efficiency through highly translational phenotypic screening. Generian has internal programs for clinically validated targets, FcRn and IL-4r alpha, as well programs focused on novel targets through a research collaboration agreement with Astellas. If you want to learn more, reach out to our team at info@generian.com